A random forest-based metabolic risk model to assess the prognosis and metabolism-related drug targets in ovarian cancer

Haoxin Zhang(Harbin Medical University), Lei Yang(Harbin Medical University), Yongchun Zuo(Inner Mongolia University), Yuqiang Xiong(Harbin Medical University), Haodong Wei(Harbin Medical University), Yu Yao(Qinghai University), Dongqing Su(Harbin Medical University)

Computers in Biology and Medicine

December 16, 2022

10.1016/j.compbiomed.2022.106432

Cited by 36

Related Papers

CGCG clinical practice guidelines for the management of adult diffuse gliomas

|Cancer Letters|2016|650

Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial

|BMJ|2022|494

Clinical practice guidelines for the management of adult diffuse gliomas

|Cancer Letters|2020|482

Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis

|The Lancet Oncology|2016|374

Temozolomide-associated hypermutation in gliomas

|Neuro-Oncology|2018|227